Metastatic Melanoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

 Breaking News
  • No posts were found

Metastatic Melanoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

January 25
07:58 2023
Metastatic Melanoma Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Metastatic Melanoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The Metastatic Melanoma therapeutics market is anticipated to change in the coming years owing to the rise in the number of incident cases of Metastatic Melanoma, improvement in the diagnosis methodologies, the launch of emerging therapies, and incremental healthcare spending across the world. The pipeline of Metastatic Melanoma is quite robust, with several products available in the developmental stage.

Metastatic Melanoma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metastatic Melanoma Market. 

The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Metastatic Melanoma Pipeline Analysis

Metastatic Melanoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Metastatic Melanoma and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic Melanoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Metastatic Melanoma Emerging Therapies – Mechanism of Action Types

  • CD8 positive T lymphocyte stimulant

  • Ras protein inhibitor

  • Immunostimulant

  • PTK2 protein inhibitors

  • Tumour necrosis factor-alpha stimulants

  • T lymphocyte replacement

  • T lymphocyte stimulant


Route of Administration

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal


Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule


Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Learn How the Ongoing Clinical & Commercial Activities will Affect the Metastatic Melanoma Therapeutic Segment @

Metastatic Melanoma Therapeutics Landscape

The treatment of Metastatic Melanoma focuses on prolonging survival, eliminating cancer, shrinking or stopping the growth of known metastases, and controlling symptomatic or risky sites of disease, thereby providing comfort. The treatment landscape of Metastatic melanoma comprises immunotherapy, targeted therapy, intralesional therapy, chemotherapy, and radiation therapy. However, surgery is also considered an option in some instances.

To further improve the treatment scenario, there are approx. 75+ key companies developing therapies for Metastatic Melanoma. Evaxion Biotech is leading the therapeutics market with its Metastatic Melanoma drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Metastatic Melanoma Therapeutics Market Include:

  • Evaxion Biotech

  • InxMed

  • AiVita Biomedical

  • Iovance Biotherapeutics

  • Viralytics

  • Merck & Co.

  • Neon Therapeutics

  • BioNTech

  • Bristol-Myers Squibb

  • Ono Pharmaceuticals

  • Cytovation AS

And Many Others

Metastatic Melanoma Drugs Covered in the Report Include:

  • EVX 01: Evaxion Biotech

  • IN 10018: InxMed

  • AV MEL 1: AiVita Biomedical

  • EVX 01: Evaxion Biotech 

  • Lifileucel: Iovance Biotherapeutics

  • Fianlimab: Regeneron Pharmaceuticals

  • NKTR-214: Nektar Therapeutics

  • IMO-2125: Idera Pharmaceuticals 

  • OBP 301: Oncolys BioPharma

  • LN-144: Iovance Biotherapeutics 

  • Ampligen: Hemispherx Biopharma

  • IPI-549 + Nivolumab: Infinity Pharmaceuticals 

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Metastatic Melanoma Current Treatment Patterns

4. Metastatic Melanoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Melanoma Late Stage Products (Phase-III)

7. Metastatic Melanoma Mid-Stage Products (Phase-II)

8. Metastatic Melanoma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Melanoma Discontinued Products

13. Metastatic Melanoma Product Profiles

14. Key Companies in the Metastatic Melanoma Market

15. Key Products in the Metastatic Melanoma Therapeutics Segment

16. Dormant and Discontinued Products

17. Metastatic Melanoma Unmet Needs

18. Metastatic Melanoma Future Perspectives

19. Metastatic Melanoma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Other Trending Healthcare Reports By DelveInsight

Infectious Disease Diagnostics Market

The global Infectious Disease Diagnostics Market was valued at USD 38.52 billion in 2021 and is estimated to grow at a CAGR of 3.80% during the forecast period (2022–2027) to reach USD 48.10 billion by 2027. The infectious disease market is slated to witness prosperity owing to factors such as the growing prevalence of infectious diseases such as COVID-19, malaria, typhoid, and others, rising incidences of epidemics and pandemics, and the growing focus on improving the safety, affordability, and usability of infectious disease diagnostics for end-users are further expected to result in the appreciable revenue growth during the forecast period (2022-2027).

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles